Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab

Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab

Here, the authors identify B lymphocyte antigen CD20 as a marker for HIV-infected T cells and provide evidence for the potential use of anti-CD20 antibodies in combination with latency reversing agents for depletion of viral reactivated CD4 T cells in patients on antiretroviral therapy.

Bibliographic Details
Main Authors: Carla Serra-Peinado, Judith Grau-Expósito, Laura Luque-Ballesteros, Antonio Astorga-Gamaza, Jordi Navarro, Jenny Gallego-Rodriguez, Mario Martin, Adrià Curran, Joaquin Burgos, Esteban Ribera, Berta Raventós, Rein Willekens, Ariadna Torrella, Bibiana Planas, Rosa Badía, Felipe Garcia, Josep Castellví, Meritxell Genescà, Vicenç Falcó, Maria J. Buzon
Format: Article
Language:English
Published: Nature Portfolio 2019-08-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-019-11556-4

Internet

https://doi.org/10.1038/s41467-019-11556-4

Similar Items